

Meeting Patients Where They Are: Validating Remote Digital Tools for Multi-Indication NMD Research



As clinical research evolves, so too must the tools we use to measure outcomes—particularly in neuromuscular disease studies, where patient burden and accessibility remain critical considerations. This 2026 C-Path Rare and Orphan Disease program webinar “**Meeting Patients Where They Are: Validating Remote Digital Tools for Multi-Indication NMD Research**,” was recorded on March 19. Dr. Tina Duong was featured, as well as a panel of experts across industry and regulatory science.

In this session, Dr. Duong explored the scientific, clinical, and regulatory considerations involved in validating video-based assessments and other digital tools across multiple NMD indications. Through both presentation and panel discussion, attendees gained valuable insights into how these approaches can:

- Enhance accessibility for patients regardless of location
- Reduce the burden of participation in clinical trials
- Generate reliable, regulatory-grade data
- Ensure innovation remains grounded in patient-centered research

The presentation will be followed by a panel discussion featuring:

- Dr. Prashant Bansal (Dyne Therapeutics)
- Dr. Michelle Campbell (U.S. Food and Drug Administration)
- Dr. Roxana Donisa Dregghici (Edgewise Therapeutics)
- Dr. Christine Guo (Ametris)

This webinar is designed for stakeholders across drug development, clinical research, regulatory science, and patient advocacy who are committed to advancing more inclusive and effective clinical trials.

Published on February 17, 2026